OOIR: Observatory of International Research

Papers

(The median citation count of Lancet Infectious Diseases is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Transaminases and serum albumin as early predictors of severe dengue – Authors' reply	1655
Environment and infectious diseases	1237
A step forward in the journey towards hookworm vaccines	901
Listeria monocytogenes: a rare, deadly cause of peritonitis	801
Surge of cutaneous leishmaniasis in Pakistan	686
Is ceftriaxone similarly effective to benzylpenicillin in neurosyphilis? – Authors' reply	667
Research in brief	596
Research in brief	594
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting	478
Role of the G20 in safe reopening of international travel	465
Attention to skin-related neglected tropical diseases	456
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect	438
Infectious disease surveillance update	372
Chronicling PEPFAR's work in Africa	368
Ordinary people in extraordinary times	360
Infectious disease surveillance update	357
Rajendra Kapila	314
Entering a labyrinth of COVID-19 stories	277
Promoting diversity and equity in publishing	277
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7	275
SARS-CoV-2 incidence and vaccine escape	267
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges	266
Adaora “Ada” Alise Adimora	263
The next chapter for Africa's genomic initiatives	255
The superiority of bivalent over monovalent booster vaccines	253

Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum	248
DNDi receives Dutch funding boost	244
COVID-19 vaccination protects children and adolescents	240
Can the USA return to pre-COVID-19 normal by July 4?	234
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study	234
Reflecting on lessons from the 2014–16 Ebola virus outbreak	218
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis	218
Bold measures to accelerate malaria elimination	216
A patient with secondary syphilis following incomplete treatment of primary infection	210
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations	210
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial	205
Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study	205
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review	203
HIV vaccine trial failure	201
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden	193
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial	190
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial	187
Threat of HIV and tuberculosis drug resistance after US funding cuts	179
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study	177
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria	169
Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines	163
Transitioning to endemicity with COVID-19 research	162
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic	162
Updated criteria for paediatric sepsis and septic shock	162
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations	161
Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial	157
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation	156
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis	155
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1	155
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C	155
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial	154
Mpox in people with past infection or a complete vaccination course: a global case series	153
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study	152
The interplay between COVID-19 restrictions and vaccination	151
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study	150
Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blin	147
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco	145
The importance of understanding the infectious microenvironment	142
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2	140
Post-viral sequelae of COVID-19 and influenza	140
Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention	139
Supporting healthcare access for refugees and migrants	138
Assessment of experimental malaria vaccine induced protection in pre-exposed populations	137
History and evolution of tuberculosis and global health	137
Election of Regional Director for the Western Pacific	136
High-dose primaquine reduces vivax relapses: time for change	134
The implications of mpox breakthrough infections on future vaccination strategies	134
Severe influenza: is there a role for antiviral combinations?	130
Sizing the reservoirs of malaria transmission: the contribution of school-aged children	130
Correction to Lancet Infect Dis 2021; 21: 962–74	129

Emil Gotschlich	128
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa	127
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world	127
Interplay of infection and vaccination in long-term protection from COVID-19	127
Immune evasiveness of SARS-CoV-2 variants and vaccine selection	126
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis	126
Global cholera resurgence—a preventable tragedy	126
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study	126
The global burden of cryptococcosis—a neglected tropical disease?	126
Worrying lack of funding for tuberculosis	123
Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study	123
Elisabeth Presterl—always looking forward	122
Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis	121
We need estimates of gonorrhoea vaccine protection and symptomaticity by sex and anatomical site	119
Super-spreaders: a historical review	118
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant	118
Addressing the shortage of cholera vaccines	116
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products—an update	115
Malaria vaccine development in Mali: a step towards transmission-blocking strategies	114
Allergic bronchopulmonary aspergillosis with chest pain as atypical symptoms	113
Correction to Lancet Infect Dis 2023; 23: e469	112
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5	111
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-0	110
Research in brief	109
Correction to Lancet Infect Dis 2021; 21: 629–36	109
Full-dose NSAIDs at the first sign of respiratory infection?	106
The response of mpox-associated inflammatory syndrome to steroid therapy	105
Theresa Ochoa—staying on top of infectious diseases in Peru	104
Infectious disease surveillance update	102
Is combination antiviral therapy for influenza the optimal approach?	101
Tuberculosis recovery in Georgia: implementing more by 24	99
Linda-Gail Bekker—a leader at the service of the world	98
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents	97
Twin threats: climate change and zoonoses	96
Curing chronic hepatitis B virus infection	95
Research in brief	93
Vaccine and surveillance implications of dengue underdetection	91
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86	88
Correction to Lancet Infect Dis 2025; 25: e47–58	88
WHO Pathogen X conference	88
Guidelines adherence as a major protective aspect to increase survival rate in patients with candidaemia in Europe	88
Research in brief	87
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia	87
Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance	87
A decentralised point-of-care testing model to address inequities in the COVID-19 response	86
New flavours of tuberculosis treatment for children	86
Assessing the burden of congenital rubella syndrome in China and evaluating mitigation strategies: a metapopulation modelling study	85
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-	84
COVID-19 mortality in Africa and Asia – Authors' reply	84
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis	83
Serpiginous-like choroiditis in ocular tuberculosis	83
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape	83
WHO's first global infection prevention and control report	82
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial	82
Effect of change in vaccine schedule on pertussis epidemiology in France: a modelling and serological study	81
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study	80
Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation	80
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?	79
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine	79
Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis	79
Statistical concerns for meta-analysis of rare events and small sample sizes – Authors' reply	78
Next-generation malaria subunit vaccines to reduce disease burden in African children	78
Vaccine pragmatism in the 21st century	78
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study	78
Amal Saif Al-Maani—fighting antimicrobial resistance	78
Outbreaks compound Brazil's flooding disaster	77
Correction to Lancet Infect Dis 2021; 21: 929–38	77
Infectious disease surveillance update	77
A step closer to elimination of meningococcal disease	76
Spreading awareness on lymphatic filariasis	75
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial	75
Re-emergence of Oropouche virus in Brazil and Latin America	74
Gender and geographical representation at infectious diseases and clinical microbiology conferences	74
Child-friendly rifapentine formulation is a game changer	74
Advancing integration: progress reported for skin NTDs	73
RH5.1/Matrix-M: highlighting blood-stage malaria vaccines	73
A tale of potential mpox reinfection	73
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial	72
Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7	72
Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa	72

Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices	72
Effectiveness of pyriproxyfen-pyrethroid and chlorfenapyr-pyrethroid long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs for malaria control in the third year post-distribution:	71
Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials	71
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3	71
Highlights from ECCMID 2022	69
Ivermectin for malaria control in mass drug administration programmes	69
Cross-protective potential of a MF59-adjuvanted quadrivalent influenza vaccine in older adults	68
Clindamycin-resistant Streptococcus pyogenes in Chinese children	68
The urgent need to scale-up fungal diagnostics in Africa	67
Is the end of gonorrhoea in sight?	67
Correction to Lancet Infect Dis 2023; 23: e259–65	67
Sir Michael Anthony Epstein	67
Imprinted hybrid immunity against XBB reinfection	67
Correction to Lancet Infect Dis 2023; published online Aug 3. https://doi.org/10.1016/S1473-3099(23)00344-4	67
On the frontline during the COVID-19 pandemic	67
Lessons learnt from conducting a randomised clinical trial in eumycetoma	66
Research in brief	66
Pui-Ying Iroh Tam	66
Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch	65
Moxidectin versus ivermectin for strongyloidiasis control	65
Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil	65
Sleeping sickness: time for dreaming	64
Lassa fever research priorities: towards effective medical countermeasures by the end of the decade	64
The origin of SARS-CoV-2 variants of concern	64
Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2	64
Prevention of non-ventilator-associated hospital-acquired pneumonia in Switzerland: a type 2 hybrid effectiveness–implementation trial	64
Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study	63
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study	63
The spatiotemporal ecology of Oropouche virus across Latin America: a multidisciplinary, laboratory-based, modelling study	63
doxyPEP: a controversial new tool against STIs	62
Social workers and neglected tropical diseases	62
Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south	62
Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings	62
DoxyPEP: thinking towards implementation	62
National case series of group A streptococcus pleural empyema in children: clinical and microbiological features	62
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis	61
Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluste	61
Incidence and risk factors of tuberculosis among 420 854 household contacts of patients with tuberculosis in the 100 Million Brazilian Cohort (2004–18): a cohort study	61
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study	61
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster	61
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study	61
Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows	61
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial	60
Human ocular thelaziosis—a zoonosis of the eye	60
Hong Kong's fifth COVID-19 wave—the worst yet	60
Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study	60
COVID-19 mortality in Africa and Asia	60
Detective doctor decodes AIDS mystery	59
Experts react to SAGO's preliminary report	59
Lien Jih-ching	59
A new key-player for onchocerciasis elimination	58
Correction to Lancet Infect Dis 2021; 21: 677–87	58
Antibody durability at 1 year after Sputnik V vaccination	58
Infectious disease surveillance update	58
Correction to Lancet Infect Dis 2023; 23: 789	58
Monkeypox trial to begin in DR Congo	58
Zika vaccines: can we solve one problem without creating another one?	57
Antibiotic stewardship in the real world	57
Randomised controlled trials for mpox in endemic countries	57
Navigating the storm of the 1980–90s AIDS epidemic	57
Understanding the immunogenicity of RTS,S in infants	56
Alexandra King—promoting Indigenous self-determination	56
A vanquished threat or a cautionary tale?	56
Correction to Lancet Infect Dis 2025; 25: e11–12	55
Lessons from the English primary care sentinel network's response to the COVID-19 pandemic	54
Correction to Lancet Infect Dis 2022; published online Jan 25. https://doi.org/10.1016/S1473-3099(21)00586-7	54
Developing the EAVE III platform for future health crises	54
A shared history	53
Correction to Lancet Infect Dis 2021; published online Feb 1. https://doi.org/10.1016/S1473-3099(20)30738-6	53
Global measles cases up 20% in 2023	53
A step forward for Plasmodium falciparum malaria transmission-blocking vaccines	53
Learning and confirming in publicly funded antiviral trials	52
Humanitarian crisis in Tigray amidst civil war	52
A new formulation of praziquantel to achieve schistosomiasis elimination	52
Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prosp	52
Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis	52
Transmissibility of SARS-CoV-2 among fully vaccinated individuals	52
Impact of COVID-19 on migrants and refugees	52
Struggling with a new dengue epidemic in Nepal	51
Deaths of unknown cause in DR Congo	51
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African c	51
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomi	50
Understanding vancomycin nephrotoxicity augmented by β-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, and β-lactam chemistry	50
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation	49
Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study	49
Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia	49
Hospital admissions for group A streptococcal infections in England: current rates and historical perspective	49
What is the pandemic potential of avian influenza A(H5N1)?	49
Salmonella Typhimurium outbreak linked to chocolate	48
Correction to Lancet Infect Dis 2025; published online Feb 13. https://doi.org/10.1016/S1473-3099(24)00749-7	47
What chikungunya teaches us about COVID-19	47
Reporting of deaths during cholera outbreaks: case fatality ratio and community deaths	47
Correction to Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S1473-3099(23)00731-4	47
Artificial intelligence to transform public health in Africa	47
H5N1 avian influenza: tracking outbreaks with real-time epidemiological data	46